CLX · The Clorox Company
Executive Thesis
The Clorox Company (CLX) is rated Hold with a 12-month target of $100, implying approximately 5% price upside, reflecting limited near-term catalysts amid margin pressure and flat organic sales. CLX’s defensive consumer staples portfolio benefits from strong brand equity and steady demand in household and lifestyle segments, underpinning its resilient competitive moat. However, margin contraction driven by inflationary cost headwinds, inventory step-ups, and modest volume declines underscore operational challenges, while earnings gains are largely attributable to one-off items rather than sustainable growth. We recommend a neutral stance, suggesting investors maintain current exposure without incrementally accumulating or reducing shares.
Audited Fundamentals
Frequently Asked Questions: CLX
What is L2 Capital's investment rating and price target for CLX?
L2 Capital currently maintains an institutional rating of HOLD on The Clorox Company (CLX) with a 12-month target price of $100.00 (implied return: +5%), backed by Moderate conviction.
What is the core investment thesis for CLX?
The Clorox Company (CLX) is rated Hold with a 12-month target of $100, implying approximately 5% price upside, reflecting limited near-term catalysts amid margin pressure and flat organic sales. CLX’s defensive consumer staples portfolio benefits from strong brand equity and steady demand in household and lifestyle segments, underpinning its resilient competitive moat. However, margin contraction driven by inflationary cost headwinds, inventory step-ups, and modest volume declines underscore operational challenges, while earnings gains are largely attributable to one-off items rather than sustainable growth. We recommend a neutral stance, suggesting investors maintain current exposure without incrementally accumulating or reducing shares.
What are CLX's latest audited financial fundamentals?
According to audited SEC EDGAR filings, The Clorox Company reported total revenue of $7.39B (+4.0% YoY), Gross Margin of 39.4%, Free Cash Flow of $930.0M, and Net Debt of $2.28B.